Anticoagulants
description
Transcript of Anticoagulants
![Page 1: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/1.jpg)
NURS 1950Pharmacology I
1
![Page 2: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/2.jpg)
Objective 1: identify general reasons anticoagulants are given
2
![Page 3: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/3.jpg)
Objective 2: identify the cells in the body that release heparin
Objective 3: describe the actions of heparin
3
![Page 4: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/4.jpg)
Objective 4: list the appropriate routes to administer heparin
4
![Page 5: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/5.jpg)
Heparin: only parenteral administration Warfarin: oral Heparin
◦ Low doses: inhibit clotting factor Xa◦ High doses: inhibits all clotting factors◦ Effects occur immediately
5
![Page 6: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/6.jpg)
Preferred during pregnancy, PE, DVT Required for open heart surgery, renal
dialysis
6
![Page 7: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/7.jpg)
Side Effects Hemorrhage: observe hypotension,
tachycardia, petechiae, bruises May see bloody stools, pelvic pain,
headache Hypersensitivity: chills, fever, rash Antidote: protamine sulfate
7
![Page 8: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/8.jpg)
Administration◦ IV or subq◦ IM causes hematoma◦ Monitor PTT above 1.5-2 X normal is therapeutic◦ Monitor INR: between 2-3
8
![Page 9: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/9.jpg)
Enoxaparin (Lovenox): low molecular weight◦ Acts so has less potential for hemorrhage, longer
duration of action Subq administration Does not affect PT or APTT Do not give to clients allergic to pork by-
products
9
![Page 10: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/10.jpg)
Do not inject IM Do not expel air bubble from syringe before
injection Do not rub injection site
10
![Page 11: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/11.jpg)
SE to expect: hematoma with improper injection technique
SE to report: bleeding, thrombocytopenia Drug interactions: no clinically significant
interactions◦ Caution: antiplatelet or warfarin therapy
11
![Page 12: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/12.jpg)
Warfarin (Coumarin)◦ 1st oral ◦ Antidote: Vitamin K◦ Monitor protime
Needs to be 1.5 to 2X normal Monitor INR: 2-3
12
![Page 13: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/13.jpg)
Interactions◦ Heparin◦ ASA◦ Butazoladin◦ Barbiturates
13
![Page 14: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/14.jpg)
Objective 5: identify the antidote for heparin
14
![Page 15: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/15.jpg)
Objective 6: name the lab tests that are the basis to determine the effectiveness and dosage of heparin◦ PTT 60-80◦ PT 2.5-3.5◦ INR 2-3◦ APTT 25-35 is normal
2-3x baseline= therapeutic ; measured daily
15
![Page 16: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/16.jpg)
Objective 7: describe the important points regarding subcutaneous administration of heparin◦ Dose/strength◦ Injection site◦ Needle/syringe◦ Aspiration ◦ Pressure
16
![Page 17: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/17.jpg)
Objective 8: list the signs of heparin overdose◦ Bleeding ◦ VS changes◦ Thrombocytopenia ◦ White clot formation is a toxic reaction
17
![Page 18: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/18.jpg)
Objective 9: identify drugs that enhance the action of heparin◦ NSAIDs◦ ASA◦ Ginkgo biloba◦ Dipyridamole◦ Clopidogrel◦ Ticlopidine
18
![Page 19: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/19.jpg)
Objective 10: describe the action of Coumadin◦ Inhibits the activity of vitamin K—needed for
activation of clotting factors II, VII, IX and X
19
![Page 20: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/20.jpg)
Objective 11: name the lab tests done to determine the effectiveness and dosage of Coumadin
◦ 12-15 sec = Normal PT
20
![Page 21: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/21.jpg)
Objective 12: identify drugs that increase and decrease the effectiveness of Coumadin
Drugs that can increase Coumadin effects: Tylenol, ASA, dong quai, ginkgo biloba, oil of wintergreen, omeprazole
Drugs that can decrease the effects: St. John’s Wort, rose hip, barbiturates, griseofulvin, vitamin C, vitamin K
21
![Page 22: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/22.jpg)
Objective 13: discuss other select anticoagulant agents◦ Fibrinolytic agents◦ Antiplatelet drugs
22
![Page 23: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/23.jpg)
Suppress aggregation platelets Prevent arterial thrombus ASA single dose; 5 gr or less
◦ Doubles bleeding time for 4-7 days◦ Reduces MI, TIAs, CVAs
23
![Page 24: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/24.jpg)
Amicar◦ Inactivates plasminogen ◦ USE: given IV to reduce hemorrhage in 1-2 hrs
◦ Precaution: no ASA ; DIC is likely problem
24
![Page 25: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/25.jpg)
Streptokinase◦ Promotes plasminogen to plasmin◦ Uses
Acute coronary thrombi DVT Massive pulmonary emboli
◦ Nursing interventions: Monitor ECG q 15 min during 1st hr of infusion Monitor LOC (intercranial hemorrhage)
25
![Page 26: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/26.jpg)
MI: must give within 6 hours DVT: give within 3 days PE: no more than 5-7 days
26
![Page 27: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/27.jpg)
Side Effects Hemorrhage: use Amicar Fever, allergic reaction
Drug given IV
27
![Page 28: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/28.jpg)
Urokinase◦ Promotes plasminogen to plasmin
28
![Page 29: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/29.jpg)
TPA: tissue type plasminogen activator (Activase)◦ Synthetic◦ Clears coronary artery◦ SE: bleeding
29
![Page 30: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/30.jpg)
Objective 14: discuss the indications for antiplatelet drugs◦ Previous MI, CVA, TIA◦ Conditions that predispose to clot formation
Some used in combination post cardiac valve replacement
Peripheral arterial disease Atrial fibrillation Unstable angina
30
![Page 31: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/31.jpg)
Objective 15: describe the nursing responsibilities associated with a client receiving an anticoagulant, including specific safety considerations
31
![Page 32: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/32.jpg)
Dosage schedules Hydration Lab data Preventing clot formation Patient teaching
◦ Follow-up◦ Safety
32
![Page 33: Anticoagulants](https://reader036.fdocuments.us/reader036/viewer/2022062410/56815225550346895dc06b59/html5/thumbnails/33.jpg)
◦ Medic alert bracelet◦ Symptoms to report◦ Do not take OTC meds without consulting MD
33